Ruzasvir is under clinical development by Atea Pharmaceuticals and currently in Phase I for Hepatitis C. According to GlobalData, Phase I drugs for Hepatitis C have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ruzasvir’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ruzasvir is under development for the treatment of hepatitis C infection. The drug candidate is administered orally and targets NS5A antigen.
Atea Pharmaceuticals overview
Atea Pharmaceuticals (Atea) is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases including herpesvirus, hepatitis B, hepatitis C infections and HIV/AIDS. The company utilizes its purine nucleotide prodrug platform for the development of its products. Pipeline products of the company include AT527 for the treatment of COVID-19, AT-752 for dengue, AT-787 for Hepatitis C (HCV), AT-889 and AT-934 for the treatment of respiratory syncytial virus infection. Atea Pharmaceuticals is headquartered in Boston, Massachusetts, the US.
For a complete picture of Ruzasvir’s drug-specific PTSR and LoA scores, buy the report here.